Bo Lei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bo Lei has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Jianyu Liu
Department of Breast Surgery, Harbin Medical University Cancer Hospital, No. 150 Haping Road, Nangang District, Harbin 150081, China
1 shared publication - Jinsong Wang
Department of Oncology Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
1 shared publication Leiguang Ye
Department of Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China
1 shared publication- Lin Li
Harbin Medical University Cancer Hospital, Cancer Research Institute, Harbin Medical University, Harbin 150081, China
1 shared publication Sifan Zhang
Department of Neurobiology, Harbin Medical University, Harbin 150081, China
1 shared publication- Tong Liu
Department of Oncology Surgery, Harbin Medical University Cancer Hospital, Harbin, China
1 shared publication
Latest Publications
- 24 May 2023
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 73, 27-39
Exosomes-regulated lipid metabolism in tumorigenesis and cancer progression
- 24 May 2023
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 73, 27-39
Exosomes-regulated lipid metabolism in tumorigenesis and cancer progression
- Open Access
Single-Cell Proteomic Profiling Identifies Nanoparticle Enhanced Therapy for Triple Negative Breast Cancer Stem Cells
Breast cancer remains a major cause of cancer-related deaths in women worldwide. Chemotherapy-promoted stemness and enhanced stem cell plasticity in breast cancer is a cause for great concern. The discovery of drugs targeting BCSCs was suggested to be an important advancement in the establishment of therapy that improves the efficacy of chemotherapy. In this work, by using single-cell mass cytometry, we observed that stemness in spheroid-forming cells derived from MDA-MB-231 cells was significantly increased after doxorubicin administration and up-regulated integrin αvβ3 expression was also observed. An RGD-included nanoparticle (CS-V) was designed, and it was found that it could promote doxorubicin’s efficacy against MDA-MB-231 spheroid cells. The above observations suggested that the combination of RGD-included nanoparticles (CS-V) with the chemo-drug doxorubicin could be developed as a potential therapy for breast cancer.
Open AccessSingle-Cell Proteomic Profiling Identifies Nanoparticle Enhanced Therapy for Triple Negative Breast Cancer Stem Cells
Breast cancer remains a major cause of cancer-related deaths in women worldwide. Chemotherapy-promoted stemness and enhanced stem cell plasticity in breast cancer is a cause for great concern. The discovery of drugs targeting BCSCs was suggested to be an important advancement in the establishment of therapy that improves the efficacy of chemotherapy. In this work, by using single-cell mass cytometry, we observed that stemness in spheroid-forming cells derived from MDA-MB-231 cells was significantly increased after doxorubicin administration and up-regulated integrin αvβ3 expression was also observed. An RGD-included nanoparticle (CS-V) was designed, and it was found that it could promote doxorubicin’s efficacy against MDA-MB-231 spheroid cells. The above observations suggested that the combination of RGD-included nanoparticles (CS-V) with the chemo-drug doxorubicin could be developed as a potential therapy for breast cancer.